Latest News
All Times Eastern
- Barron's Being a Utility Executive Is Getting Harder. Tesla Is to Blame.
- ‘It’s caused a lot of tension in our marriage’: My wife’s family comes visit, hides food and never cleans up. How do we get rid of them?
- Barron's China’s AI Clout Might Be Overstated. What to Know.
- Barron's This Company Makes Costco and Amazon’s Store Brands. Its Stock Is a Buy.
- Barron's This Carbon-Capture Stock Has Big Plans. Why It’s a Buy.
- Barron's Forget Apple and Nvidia. Why June Belongs to Small-Caps.
- Barron's Market Gains as Wall of Worry Crumbles. What Happens Next.
- Judge in FTX bankruptcy rejects media challenge, says customer names can remain secret
- Barron's Commercial Traders Are Net Long Copper. That’s a Good Sign for the Red Metal.
- Mark Zuckerberg says Meta may be ‘primary beneficiary’ of Apple Vision Pro headset
to be replaced
Eisai Co. Ltd.
ESALFUS
6.93
9.35%
Closed
$ 81.03
| Previous Close |
|---|
| $74.10 |
Volume: 5.15K
65 Day Avg: 519.12
75.50
Day Range
81.03
40.00
52 Week Range
81.03
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
ESALF Overview
Key Data
- Open $76.48
- Day Range 75.50 - 81.03
- 52 Week Range 40.00 - 81.03
- Market Cap $21.26B
- Shares Outstanding N/A
- Public Float 228.72M
- Beta N/A
- Rev. per Employee $485.17K
- P/E Ratio 55.67
- EPS $1.46
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest N/A
- % of Float Shorted N/A
- Average Volume 519.12
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 15
Full Ratings
Recent News
Israel stocks fall, weighed by banks, tech
Shares of Teva slip after the company gets clearance from the U.S. Food and Drug Administration to market a generic form of Aricept to treat Alzheimer’s.
Japan shares slip as yen gains pressure exporters
TOKYO (MarketWatch) -- Japanese shares fell Wednesday morning in Tokyo as fresh strength in the yen pressured shares of major exporters. The Nikkei Stock Average was down 0.5% at 9,556.43 and the broader Topix fell 0.4% a...
Modest moves for Asia as Australia greets new PM
Asian markets log modest moves Thursday, pressured by the Federal Reserve's downgrade of its outlook on the U.S. economy. Australia's resource shares outperform amid optimism that the nation's new prime minister will softe...
Japanese shares end the morning session higher
TOKYO (MarketWatch) -- Japanese shares finished modestly higher for the morning session, reversing from a weak open as traders bought stocks after a two-day decline. The Nikkei Stock Average rose 0.2% to 9,940.37, and the ...
Breaking Japan shares climb as chip maker shares advance
TOKYO (MarketWatch) -- Japanese shares climbed Thursday morning in Tokyo with the Nikkei 225 Average gaining 1.5% to 10,552.92.73 and the broader Topix adding 1.1% to 942.34. Shares of Elpida Memory Inc. and Tokyo Electro...
Japanese drug makers put up a fight
Japanese drug makers are facing some stiff competition but they’re holding their ground and fighting back as they work to boost overseas deals and raise their share of the generic-drug market.
Takeda tumbles on fears over delay in drug's approval
Shares of Takeda Pharmaceutical trade sharply lower in Tokyo, with selling fueled by concerns that U.S. regulatory approval could be delayed for a key diabetes medication.
Israel stocks at records; TA-25 up near 21% for `07
TEL AVIV (MarketWatch) -- Israel stocks closed at record highs on Sunday, with Teva higher after losing a bidding battle for a drugmaker and agrichemicals giant Makhteshim-Agan up after reporting that first-quarter net inc...
The 7 Best Growth Stocks to Buy for February 2023
on InvestorPlace.com
Biogen, Eisai May Have an Alzheimer’s Beater on Their Hands
The ongoing battle against Alzheimer's disease may have a new weapon soon. Pharmaceutical firm Biogen (NASDAQ:BIIB), backed up by Eisai (OTCPK:ESALF), just landed a big nod from the FDA that will let its Alzheimer's therap...
on TipRanks.com
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
on Benzinga.com
Eisai Co. Ltd.
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Ono Pharmaceutical Co. Ltd. ADR | $9.35B | |
| Omeros Corp. | $475.61M |